Sugi Predict

Sugi Predict / Targets / KDM5C

KDM5C

Lysine-specific demethylase 5C · P41229 · KDM5C on Sugi Atlas →

26,484 patent compounds predicted against KDM5C, 15,740 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL528024 SCHEMBL528024 0.61 12/20
SCHEMBL449879 SCHEMBL449879 0.68 9/20
SCHEMBL70700 SCHEMBL70700 0.78 8/20
SCHEMBL528023 SCHEMBL528023 0.75 8/20
Dipyridyl Dipyridyl (SCHEMBL213432) 0.70 7/20
SCHEMBL118817 SCHEMBL118817 0.61 7/20
SCHEMBL528803 SCHEMBL528803 0.53 7/20
SCHEMBL481039 SCHEMBL481039 0.52 7/20
SCHEMBL72377 SCHEMBL72377 1.00 6/20
SCHEMBL186166 SCHEMBL186166 0.63 6/20
SCHEMBL40395 SCHEMBL40395 0.61 6/20
SCHEMBL220538 SCHEMBL220538 0.61 6/20
SCHEMBL353289 SCHEMBL353289 0.61 6/20
SCHEMBL509374 SCHEMBL509374 0.50 6/20
SCHEMBL40123 SCHEMBL40123 0.61 5/20
SCHEMBL50347 SCHEMBL50347 0.50 5/20
SCHEMBL167219 SCHEMBL167219 0.50 5/20
Succinylacetone Succinylacetone (SCHEMBL503918) 1.00 4/20
SCHEMBL218098 SCHEMBL218098 0.65 4/20
Levulinic Acid Levulinic Acid (SCHEMBL113572) 0.60 4/20

Clinical trials — most relevant to KDM5C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
The Danish TURNER Cryopreservation Study nanRECRUITING
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM5C binder may also engage these)

ProteinNameSimilarity
P41230 — 1.000 P41230 →
KDM5D Lysine-specific demethylase 5D 1.000 landscape →
Q5XUN4 — 1.000 Q5XUN4 →
Q6IQX0 — 1.000 Q6IQX0 →
Q80Y84 — 1.000 Q80Y84 →
Q30DN6 — 1.000 Q30DN6 →
Q3UXZ9 — 1.000 Q3UXZ9 →
KDM5B Lysine-specific demethylase 5B 1.000 landscape →
KAT8 Histone acetyltransferase KAT8 0.999 landscape →
A1YVX4 — 0.998 A1YVX4 →
Q61T02 — 0.997 Q61T02 →
Q38JA7 — 0.997 Q38JA7 →
KDM5A Lysine-specific demethylase 5A 0.997 landscape →
Q5F3R2 — 0.997 Q5F3R2 →
Q9VMJ7 — 0.996 Q9VMJ7 →
Q62240 — 0.996 Q62240 →
Q9H1H9 — 0.996 Q9H1H9 →
P25799 — 0.995 P25799 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.995 landscape →
KDM1A Lysine-specific histone demethylase 1A 0.995 landscape →
KDM4B Lysine-specific demethylase 4B 0.995 landscape →
Q7Z3E5 — 0.994 Q7Z3E5 →
Q6C710 — 0.994 Q6C710 →
A3KMI0 — 0.994 A3KMI0 →
Q6PGC1 — 0.994 Q6PGC1 →
Q5BJS0 — 0.994 Q5BJS0 →
Q12756 — 0.994 Q12756 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.993 landscape →
D3YWQ0 — 0.993 D3YWQ0 →
O43150 — 0.993 O43150 →